Dashboard
1
Poor Management Efficiency with a low ROCE of 9.81%
- The company has been able to generate a Return on Capital Employed (avg) of 9.81% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 5.98% and Operating profit at -22.65% over the last 5 years
4
The company has declared positive results in Jun'2026 after 4 consecutive negative quarters
5
With ROE of 3.01%, it has a very expensive valuation with a 2.13 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 26,247 Million (Large Cap)
71.00
NA
0.55%
0.73
3.01%
2.67
Revenue and Profits:
Net Sales:
2,577 Million
(Quarterly Results - Jun 2026)
Net Profit:
369 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.96%
0%
15.96%
6 Months
8.3%
0%
8.3%
1 Year
-26.09%
0%
-26.09%
2 Years
5.41%
0%
5.41%
3 Years
-1.37%
0%
-1.37%
4 Years
-8.65%
0%
-8.65%
5 Years
-4.39%
0%
-4.39%
Zhejiang Huahai Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.98%
EBIT Growth (5y)
-22.65%
EBIT to Interest (avg)
4.77
Debt to EBITDA (avg)
3.64
Net Debt to Equity (avg)
0.60
Sales to Capital Employed (avg)
0.52
Tax Ratio
34.81%
Dividend Payout Ratio
55.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.41%
ROE (avg)
11.11%
Valuation key factors
Factor
Value
P/E Ratio
71
Industry P/E
Price to Book Value
2.13
EV to EBIT
76.42
EV to EBITDA
24.61
EV to Capital Employed
1.65
EV to Sales
3.29
PEG Ratio
NA
Dividend Yield
2.43%
ROCE (Latest)
2.16%
ROE (Latest)
3.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
2,577.40
2,335.40
10.36%
Operating Profit (PBDIT) excl Other Income
760.60
535.10
42.14%
Interest
58.50
63.10
-7.29%
Exceptional Items
4.80
4.80
Consolidate Net Profit
368.70
398.30
-7.43%
Operating Profit Margin (Excl OI)
188.00%
111.00%
7.70%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 10.36% vs 7.21% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -7.43% vs 371.69% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
8,539.10
9,493.20
-10.05%
Operating Profit (PBDIT) excl Other Income
1,591.90
2,489.30
-36.05%
Interest
239.40
226.10
5.88%
Exceptional Items
17.40
-83.30
120.89%
Consolidate Net Profit
227.30
1,107.50
-79.48%
Operating Profit Margin (Excl OI)
66.40%
164.00%
-9.76%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -10.05% vs 14.88% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -79.48% vs 35.52% in Dec 2024
About Zhejiang Huahai Pharmaceutical Co., Ltd. 
Zhejiang Huahai Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






